FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973

Baudy, Andreas R; Dogan, Taner; Flores-Mercado, Judith E; Hoeflich, Klaus P; Su, Fei; van Bruggen, Nicholas; Williams, Simon-Peter

doi:10.1186/2191-219X-2-22

EJNMMI Research

Article metrics
Last updated: Fri, 19 Apr 2024 11:39:17 Z

FDG-PET is a good biomarker of both early response and acquired resistance in BRAF^V600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973

Access & Citations

7139

Article Accesses
49

Web of Science
46

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.